Lung Cancer | Specialty

Targeting the Immune System in Non-Small Cell Lung Cancer

August 21st 2013

Case Study: Treating KRAS-Mutant Adenocarcinoma

August 21st 2013

Case Study: Progression on ALK Inhibitors in NSCLC

August 21st 2013

Case Study: MET and ALK Targeted Therapies in NSCLC

August 21st 2013

Case Study: Second-Line Treatment of Adenocarcinoma

August 21st 2013

PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

August 21st 2013

Case Study: Mutation-Negative Patient With Adenocarcinoma

August 21st 2013

Case Study: Maintenance Therapy in Squamous NSCLC

August 21st 2013

Case Study: Treating an Elderly Patient With Squamous NSCLC

August 21st 2013

Bonnie Addario on Lung Cancer Support Groups

August 19th 2013

Bonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Dr. Brahmer on the Future of Antibodies for Lung Cancer

August 16th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the future of antibodies, including nivolumab, for the treatment of lung cancer.

Dr. Carbone on Immunotherapy Research in Lung Cancer

August 15th 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

Dr. Vokes on Multimodality Therapy for Lung Cancer

August 14th 2013

Everett E. Vokes, MD, Giant of Cancer Care in Head and Neck from University of Chicago Medicine and Biological Sciences, discusses multimodality therapy for lung cancer.

Dr. Langer Discusses Afatinib in EGFR-Positive NSCLC

August 13th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

First-Line Necitumumab Improves Survival in Metastatic Squamous NSCLC

August 13th 2013

A phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.

Dr. Mok on Plasma Testing Approaches in Lung Cancer

August 9th 2013

Tony S.K. Mok, BMSc, MD, FRCPC, from the Chinese University of Hong Kong, discusses different plasma testing approaches for patients with lung cancer.

Dr. Wakelee on Nintedanib Plus Chemotherapy in NSCLC

August 9th 2013

Heather Wakelee, MD, from the Stanford University School of Medicine, describes two phase III trials that focused on the second-line nintedanib plus chemotherapy to treat patients with advanced non-small cell lung cancer.

Dr. Scagliotti on Lung Cancer Treatment-Related Toxicities

August 7th 2013

Giorgio V. Scagliotti, MD, PhD, Head, from the University of Turin, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Dr. Herbst on Immunotherapy in Lung Cancer

August 2nd 2013

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.